Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Bausch Health Americas, Inc.
Open-Label study designed to assess the safety and plasma PK of tretinoin and relevant metabolites after topical dermal application of IDP-121 lotion in subjects with moderate to severe acne vulgaris under maximal use conditions.
Age
9–17
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
Male or female, between the ages of 9 and \<17 years (16 years 11 months inclusive).
Written and oral informed consent must be obtained. Subjects less than age of consent must sign an assent for the study and a parent or legal guardian must sign the informed consent.
Subject must have a score of 3 (moderate) to 4 (severe) on the Evaluator's Global Severity Assessment at the screening and baseline visit in the facial area.
Subjects with facial acne inflammatory lesions count no less than 20 but no more than 40.
Subjects with facial acne non-inflammatory lesions count no less than 20 but no more than 100.
You may not be if
Use of investigational drug or device within 30 days of enrollment or participation in research study or concurrent study with this study.
Any dermatological conditions on the face that could interfere with clinical evaluations acne conglobate, acne fulminans, secondary acne, perioral dermatitis, clinical significant rosacea, gram negative folliculitis.
Any underlying disease(s) or some other dermatological condition of the face that requires the use of interfering topical or systemic therapy or makes evaluations and lesion count inconclusive.
Subjects with facial beard or mustache that could interfere with any study assessments.
